Balan V - Search Results

1

CRISPR technology for immuno-oncology applications.

Wang J, Balan V, Marincola F. Wang J, et al. Among authors: balan v. Methods Enzymol. 2020;635:251-266. doi: 10.1016/bs.mie.2019.05.018. Epub 2019 Jun 8. Methods Enzymol. 2020. PMID: 32122549 Review.

2

The CRISPR System and Cancer Immunotherapy Biomarkers.

Balan V, Wang J. Balan V, et al. Methods Mol Biol. 2020;2055:301-322. doi: 10.1007/978-1-4939-9773-2_14. Methods Mol Biol. 2020. PMID: 31502158

3

Contextual reprogramming of CAR-T cells for treatment of HER2⁺ cancers.

Yang Z, Li L, Turkoz A, Chen P, Harari-Steinfeld R, Bobbin M, Stefanson O, Choi H, Pietrobon V, Alphson B, Goswami A, Balan V, Kearney A, Patel D, Yang J, Inel D, Vinod V, Cesano A, Wang B, Roh KH, Qi LS, Marincola FM. Yang Z, et al. Among authors: balan v. J Transl Med. 2021 Nov 7;19(1):459. doi: 10.1186/s12967-021-03132-6. J Transl Med. 2021. PMID: 34743703 Free PMC article.

4

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients.

Nakajima K, Balan V, Raz A. Nakajima K, et al. Among authors: balan v. Cancer Metastasis Rev. 2021 Mar;40(1):297-302. doi: 10.1007/s10555-020-09932-4. Epub 2020 Sep 14. Cancer Metastasis Rev. 2021. PMID: 32929561 Free PMC article. Review.

5

Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment.

Wang Y, Nangia-Makker P, Balan V, Hogan V, Raz A. Wang Y, et al. Among authors: balan v. Cell Death Dis. 2010 Nov 18;1(11):e101. doi: 10.1038/cddis.2010.79. Cell Death Dis. 2010. PMID: 21368866 Free PMC article.

6

Galectin-3 regulates p21 stability in human prostate cancer cells.

Wang Y, Balan V, Kho D, Hogan V, Nangia-Makker P, Raz A. Wang Y, et al. Among authors: balan v. Oncogene. 2013 Oct 17;32(42):5058-65. doi: 10.1038/onc.2012.528. Epub 2012 Nov 19. Oncogene. 2013. PMID: 23160381 Free PMC article.

7

The significance of galectin-3 as a new basal cell marker in prostate cancer.

Wang Y, Balan V, Gao X, Reddy PG, Kho D, Tait L, Raz A. Wang Y, et al. Among authors: balan v. Cell Death Dis. 2013 Aug 1;4(8):e753. doi: 10.1038/cddis.2013.277. Cell Death Dis. 2013. PMID: 23907467 Free PMC article.

8

Galectin-3: a possible complementary marker to the PSA blood test.

Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, Heilbrun L, Raz A, Heath E. Balan V, et al. Oncotarget. 2013 Apr;4(4):542-9. doi: 10.18632/oncotarget.923. Oncotarget. 2013. PMID: 23625538 Free PMC article.

9

Autocrine motility factor modulates EGF-mediated invasion signaling.

Kho DH, Zhang T, Balan V, Wang Y, Ha SW, Xie Y, Raz A. Kho DH, et al. Among authors: balan v. Cancer Res. 2014 Apr 15;74(8):2229-37. doi: 10.1158/0008-5472.CAN-13-2937. Epub 2014 Feb 27. Cancer Res. 2014. PMID: 24576828 Free PMC article.

10

Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway.

Gao X, Balan V, Tai G, Raz A. Gao X, et al. Among authors: balan v. Oncotarget. 2014 Apr 30;5(8):2077-84. doi: 10.18632/oncotarget.1786. Oncotarget. 2014. PMID: 24809457 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

304 results

Search Page